<DOC>
	<DOCNO>NCT02745509</DOCNO>
	<brief_summary>The investigator study aim explore potential function extensive intraoperative peritoneal lavage improve overall survival progression-free survival locally advance gastric cancer curative resection . Hypothesis : Overall survival progression-free survival locally advance gastric cancer improve extensive intraoperative peritoneal lavage .</brief_summary>
	<brief_title>Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy Locally Advanced Gastric Cancer ( EIPL )</brief_title>
	<detailed_description>Gastric cancer one frequently common cancer remain third lead cause death among malignant tumor world . Surgery always consider effective treatment . While significant surgical technique perioperative management dramatically improve survival patient advance gastric cancer , patient T4 stage serosal-positive gastric cancer often suffer recurrence peritoneal dissemination , prognosis patient extremely poor . Despite curatively resect , Peritoneal metastasis complete implantation peritoneal free cancer cell exfoliate serosa-invasive tumor . Therefore , thing need do eliminate free exfoliate cancer cell peritoneal line order reduce risk peritoneal recurrence . A multi-institutional prospective , randomized Phase III trial launch Kuramoto recently . The trail intend demonstrate superiority overall survival addition Extensive Intraoperative peritoneal Lavage ( EIPL ) standard treatment patient with≥T3 carcinoma stomach . Based the'limiting dilution theory ' , total distal gastrectomy D2 lymphadenectomy , peritoneal cavity extensively rinse 10 time 1 L physiological saline time , follow complete aspiration fluid . In total , 10 L saline use . In study , EIPL-IPC group significantly low incidence peritoneal recurrence . Furthermore , 5-year overall survival rate patient EIPL-IPC group ( 43.8 % ) significantly well intraperitoneal chemotherapy ( IPC ) group ( 4.6 % ) surgery-alone group ( 0 % ) . All , EIPL easy carry , safe inexpensive . Therefore , gastrectomy EIPL new standard treatment gastric cancer . To ensure quality study , two interim analysis plan half completion study respectively . The Data Safety Monitoring Committee independently review interim analysis stop study ahead schedule necessary . Furthermore , improve study progress quality , in-house interim monitoring perform .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Lower age limit research subject 18 year old upper age limit 80 year old . 2 . ECOG score standard ( ECOG）performance status 0 1 expect survive 6 month . 3 . Without malignancy . 4 . Written informed consent patient . 5 . Histologically proven primary gastric adenocarcinoma . 6 . Patients plan open gastrectomy . 7 . Patients T3 ( subserosal ) T4 ( serosal ) disease base Ultrasound gastroscopy intraoperative inspection N stag M0 gastric cancer . 8 . No preoperative neoadjuvant chemotherapy . 9 . Length esophageal invasion≤3cm need thoracotomy resection . 10 . Intraoperative inclusion criterion : 1 . Clinically T3 , T4a T4b . 2 . Clinically H0 M0 . No peritoneal dissemination Distant metastases . 3 . Possible R0 surgery . 1 . Female pregnancy lactation . 2 . Supraclavicular lymph node metastases，pelvis ovarian implantation，peritoneal dissemination，liver，lung bone metastasis . 3 . Massive ascites cachexia . 4 . Patients participate clinical trail currently，or participate trail within 1 month . 5 . Without history stomach esophageal cancer , include stromal tumor，sarcoma，lymphoma carcinoid . 6 . Suffering serious disease , include cardiovascular , respiratory , kidney , liver disease , complicate poorly control hypertension , diabetes , mental disorder disease . 7 . Patients poor compliance consider poor compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Extensive Intraoperative Peritoneal Lavage</keyword>
	<keyword>EIPL</keyword>
	<keyword>Gastric Cancer</keyword>
</DOC>